Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YFC-RUSS
- Development stage
- Unknown
- Lead developer
- Yifan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YFC-RUSS is a small molecule drug candidate developed by Suzhou Yifan Pharmaceutical (a subsidiary of Yifan Pharmaceutical) for the treatment of postpartum lactation insufficiency (hypogalactia). Classified as a Class 1 innovative drug in China, it functions as a galactagogue by acting as a dopamine D2 receptor antagonist. By blocking the inhibitory effect of dopamine on the pituitary gland, the drug promotes the secretion of prolactin, which in turn stimulates the production of breast milk. YFC-RUSS is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy female subjects.
- Other names
- YFC-RUSS
02
Targets
DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on YFC-RUSS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YFC-RUSS.